Despite the plethora of CD/LD formulations available to address the increasing “off time” that accompanies progressive PD, what are the advantages and indications of the newly FDA-approved CD/LD scored, fractionable dosing formulation?

Despite the plethora of CD/LD formulations available to address the increasing “off time” that accompanies progressive PD, what are the advantages and indications of the newly FDA-approved CD/LD scored, fractionable dosing formulation?

Despite the plethora of CD/LD formulations available to address the increasing “off time” that accompanies progressive PD, what are the advantages and indications of the newly FDA-approved CD/LD scored, fractionable dosing formulation?


Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

Laxman Bahroo, DO, FAAN

Laxman Bahroo, DO, FAAN

Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.